Dr Tamsin Dewé

Veterinary Medicines Directorate, UK

BVSc(Hons) BAnimSc MSc MRes PhD MRCVS

Research interests: antimicrobial resistance (AMR), One Health, infectious diseases, disease control, epidemiology, mathematical modelling, evidence-based policy

Tamsin is an expert in AMR and oversees the UK’s national programmes of AMR surveillance in animals, alongside a portfolio of related research. Tamsin has led a substantial expansion of the UK’s surveillance of AMR in animals, working with governmental and non-governmental partners to generate crucial new evidence on AMR in livestock, fish, dogs, and cats. She is constantly seeking to improve the way data is generated and utilised to support evidence-based policy-making around AMR, particularly in veterinary medicine and One Health.

Tamsin qualified as a veterinarian at the University of Melbourne, and has masters degrees in infectious disease control and epidemiology from the Royal Veterinary College and Imperial College London, respectively. Her PhD, also from the Department of Infectious Disease Epidemiology (DIDE) at Imperial, focused on mathematical and statistical modelling of the associations between antimicrobial use and resistance in different populations.

Dr Tine Rikke Jørgensen

WHO, Denmark

Global Public Health Specialist

Tine Rikke Jørgensen is a global public health professional with over 25 years of experience at the intersection of public health, pharmaceutical innovation, and global health policy. She is dedicated to cross-sector partnerships and committed to translating scientific innovation into equitable, evidence-based health solutions.

She is at the Globe Institute, University of Copenhagen, in the phage biodiscovery group. The Globe Institute is part of the Faculty of Health and Medical Sciences and advances interdisciplinary research bridging natural sciences, medicine, and the humanities.

Tine previously served with WHO/Europe, where she led innovation in antimicrobial resistance (AMR), including the launch of the “Vintage Innovation” workstream to strengthen the evidence base for bacteriophage therapy within a One Health framework. Her WHO career spans more than a decade and includes authorship of the One Health Priority Research Agenda on AMR, developed in collaboration with FAO, WOAH, and UNEP.

She has held senior global roles in the private sector at Sanofi Pasteur, LEO Pharma, Janssen, and Lundbeck, driving global market access strategies, health economics, and policy across infectious diseases, immunology, and dermatology.

Dr Chantal Morel

KPM Center for Public Management

Head of AMR Research

Chantal Morel is a health economist specialising in antimicrobial resistance (AMR). Her research focuses on quantifying the economic burden of AMR and evaluating interventions that can reduce its impact on health systems and society.

She examines strategies at the point of prescribing—such as incentives to improve stewardship—in both human and animal health settings, aiming to optimize antibiotic use and slow the spread of resistance.

Her work also explores new financing and structural arrangements to strengthen innovation in the antibiotic pipeline, with the goal of producing better products, improving surveillance of resistance, and expanding sustainable use measures across health systems.

In addition, Chantal advocates for policies that increase equitable access to antibiotics in regions where current supply does not meet clinical needs, contributing to a more resilient global response to AMR.